Cargando…
Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
The aim of the present study was to manufacture new orally disintegrating tablets containing nimodipine–hydroxypropyl-β-cyclodextrin and nimodipine–methyl-β-cyclodextrin inclusion complexes. For obtaining a better quality of the manufactured tablets, three methods of the preparation of inclusion com...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955142/ https://www.ncbi.nlm.nih.gov/pubmed/35335371 http://dx.doi.org/10.3390/molecules27062012 |
_version_ | 1784676265576366080 |
---|---|
author | Novac, Marian Musuc, Adina Magdalena Ozon, Emma Adriana Sarbu, Iulian Mitu, Mirela Adriana Rusu, Adriana Gheorghe, Daniela Petrescu, Simona Atkinson, Irina Lupuliasa, Dumitru |
author_facet | Novac, Marian Musuc, Adina Magdalena Ozon, Emma Adriana Sarbu, Iulian Mitu, Mirela Adriana Rusu, Adriana Gheorghe, Daniela Petrescu, Simona Atkinson, Irina Lupuliasa, Dumitru |
author_sort | Novac, Marian |
collection | PubMed |
description | The aim of the present study was to manufacture new orally disintegrating tablets containing nimodipine–hydroxypropyl-β-cyclodextrin and nimodipine–methyl-β-cyclodextrin inclusion complexes. For obtaining a better quality of the manufactured tablets, three methods of the preparation of inclusion complexes, in a 1:1 molar ratio, were used comparatively; namely, a solid-state kneading method and two liquid state coprecipitation and lyophilization techniques. The physical and chemical properties of the obtained inclusion complexes, as well as their physical mixtures, were investigated using Fourier transformed infrared spectroscopy, scanning electron microscopy, X-ray diffraction analyses, and differential scanning calorimetry. The results showed that the lyophilization method can be successfully used for a better complexation. Finally, the formulation and precompression studies for tablets for oral dispersion, containing Nim–HP-β-CD and Nim–Me-β-CD inclusion complexes, were successfully assessed. |
format | Online Article Text |
id | pubmed-8955142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89551422022-03-26 Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes Novac, Marian Musuc, Adina Magdalena Ozon, Emma Adriana Sarbu, Iulian Mitu, Mirela Adriana Rusu, Adriana Gheorghe, Daniela Petrescu, Simona Atkinson, Irina Lupuliasa, Dumitru Molecules Article The aim of the present study was to manufacture new orally disintegrating tablets containing nimodipine–hydroxypropyl-β-cyclodextrin and nimodipine–methyl-β-cyclodextrin inclusion complexes. For obtaining a better quality of the manufactured tablets, three methods of the preparation of inclusion complexes, in a 1:1 molar ratio, were used comparatively; namely, a solid-state kneading method and two liquid state coprecipitation and lyophilization techniques. The physical and chemical properties of the obtained inclusion complexes, as well as their physical mixtures, were investigated using Fourier transformed infrared spectroscopy, scanning electron microscopy, X-ray diffraction analyses, and differential scanning calorimetry. The results showed that the lyophilization method can be successfully used for a better complexation. Finally, the formulation and precompression studies for tablets for oral dispersion, containing Nim–HP-β-CD and Nim–Me-β-CD inclusion complexes, were successfully assessed. MDPI 2022-03-21 /pmc/articles/PMC8955142/ /pubmed/35335371 http://dx.doi.org/10.3390/molecules27062012 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Novac, Marian Musuc, Adina Magdalena Ozon, Emma Adriana Sarbu, Iulian Mitu, Mirela Adriana Rusu, Adriana Gheorghe, Daniela Petrescu, Simona Atkinson, Irina Lupuliasa, Dumitru Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes |
title | Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes |
title_full | Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes |
title_fullStr | Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes |
title_full_unstemmed | Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes |
title_short | Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes |
title_sort | manufacturing and assessing the new orally disintegrating tablets, containing nimodipine-hydroxypropyl-β-cyclodextrin and nimodipine-methyl-β-cyclodextrin inclusion complexes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955142/ https://www.ncbi.nlm.nih.gov/pubmed/35335371 http://dx.doi.org/10.3390/molecules27062012 |
work_keys_str_mv | AT novacmarian manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT musucadinamagdalena manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT ozonemmaadriana manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT sarbuiulian manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT mitumirelaadriana manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT rusuadriana manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT gheorghedaniela manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT petrescusimona manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT atkinsonirina manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes AT lupuliasadumitru manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes |